Licensed from Genentech in late 2016, paxalisib has been the subject of ten clinical trials. Clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. In (April 2026), the company in-licensed a SETDB1-targeted epigenetic drug platform, expanding its pipeline beyond its core brain cancer focus.
Cyborg Score Rationale
Kazia operates as a clinical-stage biotech with a reasonable pipeline but faces typical biotech risks including reliance on successful trial outcomes and cash burn. The company has demonstrated ability to raise capital (January 2025 offering) and has expanded its pipeline through licensing deals (April 2026), but lacks commercialized revenue. Nasdaq compliance challenges historically and stock volatility present execution risks.
Top Insights
(April 2026) In-licensed SETDB1-targeted epigenetic drug platform from QIMR Berghofer, including AI-integrated discovery capabilities
(May 2026) Expanded clinical trial enrollment from 12 to 36 patients following encouraging safety and tolerability data
(June 2026) Appointed James Levine as CFO and Sudha Rao as Chief Scientific Officer, strengthening leadership team
Multiple ongoing clinical trials in glioblastoma, brain metastases, diffuse midline gliomas, and primary CNS lymphoma with reported encouraging interim data
Named Competitors
Genentech — Original licensor of paxalisib; major oncology and CNS drug developer
Other PI3K/mTOR pathway inhibitors — Clinical-stage and commercial-stage PI3K/Akt/mTOR inhibitors for brain cancer
Immunotherapy combinations — Established players in oncology immunotherapy with competitive brain cancer programs
Recent Developments
(June 2026) Appointed James Levine as CFO, effective June 1
(May 2026) Expanded planned enrollment from 12 to 36 patients following continued encouraging safety and tolerability data
(April 2026) In-licensed SETDB1-targeted epigenetic drug development platform from QIMR Berghofer
(January 2026) Announced NDL2, a potentially first-in-class protein degrader targeting nuclear PD-L1 for immunotherapy resistance
(January 2025) Entered $2.0 million registered direct offering of ADSs at $1.50 per share
Open the full interactive Kazia Therapeutics Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.